COMMUNIQUÉS West-GlobeNewswire

OSE Immunotherapeutics Renforce son Équipe de Direction et son Comité Exécutif
02/12/2024
OSE Immunotherapeutics Renforce son Équipe de Direction et son Comité Exécutif Nantes, France, le 2 décembre 2024, 18 heures – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) , annonce aujourd’hui le [...]
HOOPP Board of Trustees appoints Annesley Wallace as new President & CEO
02/12/2024
HOOPP announces the appointment of Annesley Wallace as the new President & Chief Executive Officer (CEO), effective April 1, 2025 TORONTO, Dec. 02, 2024 (GLOBE NEWSWIRE) -- The Healthcare of Ontario Pension Plan ( [...]
Seegnal E-Health’s ‘Virtual Digital Pharmacist’ Approved for UK Government's G-Cloud 14 Framework
02/12/2024
TEL AVIV, Israel, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Seegnal eHealth Ltd. (“Seegnal” or the “Company”), an Israeli digital health provider, today announced that its UK distributor, Digitals UK, has secured a place for [...]
Humacyte to Present at the Piper Sandler 36th Annual Healthcare Conference
02/12/2024
DURHAM, N.C., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, today [...]
Longeveron to Present at the Emerging Growth Virtual Conference on December 5, 2024
02/12/2024
MIAMI, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related [...]
Health-ISAC Announces Board Members
02/12/2024
ORMOND BEACH, Fla., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Health Information Sharing and Analysis Center ( Health-ISAC ), the non-profit world-class, industry-led sharing organization that provides the global health sector [...]
Sana Biotechnology Announces Fast Track Designation for SC291 in Relapsed/Refractory Systemic Lupus Erythematosus
02/12/2024
Fast Track designation is designed to expedite clinical development and regulatory review timelines Enrolling patients in the GLEAM trial for SC291 in B-cell mediated autoimmune diseases, including systemic lupus [...]
Stereotaxis’ GenesisX Robotic System to be Showcased for the First Time at RSNA 2024 by Neusoft Medical Systems
02/12/2024
ST. LOUIS and SHENYANG, China, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS) and Neusoft Medical Systems Co., Ltd (“Neusoft Medical Systems”) today announced that Stereotaxis’ latest GenesisX robotic system [...]
United Health Products Provides Update on Clinical Study Process
02/12/2024
MT. LAUREL, N.J., Dec. 02, 2024 (GLOBE NEWSWIRE) -- United Health Products, Inc. (OTCPK: UEEC) today provided an update on the company’s planned clinical study. As previously disclosed, United Health Products is [...]
Spectral AI Completes Truthing of Burn Center Images, Initiates Emergency Department Image Review
02/12/2024
DALLAS, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Spectral AI (NASDAQ: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on revolutionizing medical diagnostics to enable faster, more [...]
Cepham Increases Commitment to Men’s Health With Emphasis on Wellbeing and Plant-Based Ayurvedic Care
02/12/2024
SOMERSET, N.J., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Cepham is increasing its commitment to men’s health during the holiday season when men typically face more health challenges. The American Heart Association highlights [...]
Mapi Pharma is Seeking New Depot Product Partnerships
02/12/2024
Management to Participate in 7th Annual Evercore HealthCONx Conference NESS ZIONA, Israel, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Mapi Pharma Ltd., a fully integrated, late-stage clinical development biopharmaceutical [...]
Gelteq Announces Largest U.S. Customer Increases Initial Order by 50% to Meet Growing Market Demand
02/12/2024
Healthy Extracts expands order after high demand for Gelteq’s collagen and Mynus sugar blocker gels NEW YORK, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Gelteq Limited (NASDAQ: GELS) (“Gelteq” or the “Company”), a clinical and [...]
OneMedNet Announces Exciting New Collaboration with Bayer's AI Innovation Platform to Help Accelerate Healthcare AI Development
02/12/2024
MINNEAPOLIS, Dec. 02, 2024 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) ("OneMedNet" or the "Company"), a Real-World Data (RWD) platform — has announced its collaboration with Bayer's AI Innovation Platform [...]
NovelMed Receives FDA IND Approval for NM8074 (Ruxoprubart), the First Anti-Bb Alternative Pathway Blocker for Treating Primary Immunoglobulin A Nephropathy (IgAN): A Renal Disorder
02/12/2024
--- The United States FDA Clears Initiation of a Phase II Efficacy Trial in Immunoglobulin A Nephropathy (IgAN) Patients: a renal disorder Up to 50% of IgAN patients with persistent proteinuria progress to kidney [...]
Canon Medical Informatics Selected by Leading U.S. Health System to Standardize 3D Processing Capabilities in the Cloud Using Vitrea Advanced Visualization Platform
02/12/2024
MINNETONKA, Minn., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Canon Medical Informatics, Inc. has been selected by a leading U.S. health system to standardize advanced imaging capabilities across 6 sites using the Vitrea [...]
Psychemedics Corporation Announces Reverse and Forward Stock Split
02/12/2024
DALLAS, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Psychemedics Corporation (Nasdaq: PMD) (the “Company”), the world’s leading provider of hair testing for drugs of abuse, today announced that, following the approval of the [...]
Siemens Healthineers and RadNet’s Wholly-Owned Subsidiary, DeepHealth, to Collaborate Around Elevating Ultrasound Workflows with AI-Powered SmartTechnology™
01/12/2024
Siemens Healthineers and DeepHealth have signed a letter of intent to create AI-powered SmartTechnology™ to improve patient experience and operational efficiency in ultrasound. The collaboration aims to facilitate [...]
Merus annonce la publication d’un résumé sur le pétosemtamab en tant que traitement de 2e ligne et au-delà pour le CETC r/m lors de l’édition 2024 du Congrès de l’ESMO Asia
01/12/2024
– Les données intermédiaires d’une étude de phase II portant sur le pétosemtamab administré à une dose de 1 500 mg en monothérapie continuent de démontrer une activité cliniquement significative dans le traitement de 2 [...]

Pages